MRNA - Moderna, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
59.87
-2.31 (-3.72%)
At close: 4:00PM EDT

59.70 -0.17 (-0.28%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close62.18
Open58.70
Bid59.60 x 2200
Ask59.69 x 4000
Day's Range55.36 - 59.95
52 Week Range11.54 - 87.00
Volume21,701,140
Avg. Volume21,579,598
Market Cap22.225B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.50
Earnings DateAug 05, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est89.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Carnival, Royal Caribbean, and Norwegian Cruise Line Stocks Rose Today
    Motley Fool

    Why Carnival, Royal Caribbean, and Norwegian Cruise Line Stocks Rose Today

    Cruise ship stocks rallied on Monday, as optimism for COVID-19 vaccines and treatments rose. A flurry of encouraging coronavirus-related developments in recent days likely contributed to the gains in cruise ship stock prices. On Friday, Moderna (NASDAQ: MRNA) announced the commencement of its phase 2 study for its COVID-19 vaccine, mRNA-1273.

  • INSIGHT-Scientists hunt pandemic hotspots in race to test vaccines
    Reuters

    INSIGHT-Scientists hunt pandemic hotspots in race to test vaccines

    The first wave of the COVID-19 pandemic may be waning. Scientists in Europe and the United States say the relative success of draconian lockdown and social distancing policies in some areas and countries means virus transmission rates may be at such low levels that there is not enough disease circulating to truly test potential vaccines.

  • Investing.com

    Gold Little Changed Near $1,750 as U.S. Protests Square off with Reopenings

    Gold prices settled little changed near $1,750 per ounce Monday as investors tried to balance violent protests across the United States with hopes that the world’s largest economy would emerge fully from coronavirus lockdowns. The yellow metal also gave up strong early gains after vaccine maker Moderna (NASDAQ:MRNA) started a Phase 2 study of its experimental COVID-19 vaccine, and Eli Lilly (NYSE:LLY) kicked off its Phase 1 study for a potential antibody treatment. U.S. gold futures for August settled down $1.40, or 0.01%, at $1,750.30 per ounce on Comex.

  • Moderna Starts a Phase 2 Clinical Trial for Its COVID-19 Vaccine
    Motley Fool

    Moderna Starts a Phase 2 Clinical Trial for Its COVID-19 Vaccine

    Moderna (NASDAQ: MRNA) has enrolled the first participants in a phase 2 clinical trial testing mRNA-1273, its vaccine against the novel coronavirus that causes COVID-19. Moderna announced plans to start the mid-stage study in April, followed by an endorsement by the Food and Drug Administration last month. Moderna plans to enroll 600 participants in the study, with half of them being 55 years of age or older.

  • Why virus stocks are driving market volatility
    MarketWatch

    Why virus stocks are driving market volatility

    The market’s erratic response to lukewarm medical research for COVID-19 treatment and vaccine candidates isn’t expected to slow down as investors pin their hopes for an economic recovery on the high-risk biotechnology sector.

  • GlobeNewswire

    HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Announces Investigation into Moderna, Inc. (MRNA) for Possible Securities Fraud and Insider Trading, Encourages Investors with Significant Losses to Contact Firm

    SAN FRANCISCO, June 02, 2020 -- Hagens Berman urges investors in Moderna, Inc. (NASDAQ: MRNA) to submit their losses now to learn if they qualify to recover their investment.

  • MRNA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Moderna, Inc. Investigation and Encourages Investors to Contact the Firm
    PR Newswire

    MRNA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Moderna, Inc. Investigation and Encourages Investors to Contact the Firm

    Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA). Investors who purchased Moderna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mrna.

  • Exclusive: Lonza sets new goal to make Moderna COVID-19 vaccine ingredients
    Reuters

    Exclusive: Lonza sets new goal to make Moderna COVID-19 vaccine ingredients

    Lonza aims to speed completion of two commercial production lines for Moderna Inc's trial COVID-19 vaccine so manufacturing could start four to six weeks earlier than planned if the project is successful, the Swiss drugmaker's chairman said on Tuesday. Lonza, which hopes to make smaller batches of active ingredients for the U.S. biotechnology company's experimental vaccine by July, now aims to finish a commercial production line in Portsmouth, New Hampshire, a month or so earlier than its original December 2020 target, Albert Baehny told Reuters. A second commercial line, at Lonza's site in Visp, Switzerland, had been slated for completion in January or February 2021 but now could be ready in December, he added.

  • Fauci Reiterates Moderna Vaccine Data Is 'Cautiously Optimistic,' Expects Pfizer's Results To Be The Same
    Benzinga

    Fauci Reiterates Moderna Vaccine Data Is 'Cautiously Optimistic,' Expects Pfizer's Results To Be The Same

    White House Coronavirus Task Force lead member Anthony Fauci in an interview with STAT on Monday said he was disappointed with the way Moderna Inc. (NASDAQ: MRNA) chose to publish data from phase 1 clinical trial of its novel coronavirus (COVID-19) vaccine.What Happened "I didn't like that," the National Institute of Allergy and Infectious Diseases director told STAT.Fauci said the vaccine maker should have waited to get the complete data from the first phase of the study and publish it in a "reputable journal.""But the company, when they looked at the data, as all companies do, they said, wow, this is exciting. Let's put out a press release," he added.According to Fauci, the complete data is "quite similar" to the snippet Moderna published in the press release, and gives a reason to be "cautiously optimistic.""The initial data look very promising from the neutralizing antibody standpoint," the NIAID director told STAT.On other vaccines under development, Fauci said that Pfizer Inc.'s (NYSE: PFE) COVID-19 vaccine is very similar to that of Moderna's candidate, and there's no reason to believe that the results of its candidate will be any different."It's an mRNA vaccine. I'm sure that Pfizer is going to get results that are as good as the Moderna vaccine," he told STAT.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Why It Matters Moderna last week started the phase 2 clinical trial of its COVID-19 vaccine and is expecting to move to phase 3 in July.Several vaccine experts have cast doubt on the efficiency of Moderna's vaccine, as earlier reported by STAT, saying what the company published "were words, not data."Moderna Price Action Moderna shares closed 1.1% higher at $62.18 on Monday.See more from Benzinga * Novavax Begins Phase 1 Clinical Trial Of Its Coronavirus Vaccine * Moncef Slaoui To Divest Moderna Stake As He Joins White House Vaccine Accelerator * Moderna To Raise .3B In A Public Offering As Coronavirus Vaccine Trials See Progress(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day
    Business Wire

    Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day

    Moderna highlights advances in platform science and innovative vaccine research at third annual Science Day.

  • GlobeNewswire

    MODERNA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA

    NEW ORLEANS, June 01, 2020 -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is.

  • Moderna Doses First Participants In Phase 2 Study Of Coronavirus Vaccine
    Benzinga

    Moderna Doses First Participants In Phase 2 Study Of Coronavirus Vaccine

    Moderna Inc (NASDAQ: MRNA) announced late Friday it has dosed the first participants in a Phase 2 trial of its mRNA vaccine, codenamed mRNA-1273, against SARS-CoV-2, the virus that causes COVID-19.Moderna's Vaccine Update Cambridge, Massachusetts-based Moderna said first participants in the two cohorts -- adults ages 18-55 and older adults ages 55 years and above -- have been dosed.The Phase 2 study sponsored by the company will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart, with each participant receiving placebo, a 50-microgram dose or a 100-microgram dose at both vaccinations.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.The company said the participants will be followed through 12 months after the second vaccination.In mid-May, Moderna announced positive interim Phase 1 data from a NIAID-sponsored Phase 1 trial, showing dose-dependent increases in immunogenicity across three dose levels and between prime and boost within the 25-microgram and 100-microgram dose levels.Citing the data, Moderna said in Friday's release that it decided not to pursue the 250-microgram dose level in the Phase 2 study.The vaccine candidate has a Fast Track designation from the FDA. The company has received $483 million in funding from the BARDA for its coronavirus vaccine program. The company has also finalized an collaboration agreement with Swiss CDMO Lonza to enable manufacturing up to 1 billion doses of the vaccine per year.What's Next For Moderna Moderna said the NIH will submit the Phase 1 data to a peer-to-peer reviewed clinical publication.The company now plans to start the Phase 3 study in collaboration with the NIH in July, subject to finalization of the clinical protocol.MRNA Price Action Moderna shares were trading 1.64% higher at $62.51 at the time of publication Monday. Related Links: Fauci Calls Moderna's Coronavirus Vaccine Candidate 'Quite Promising'Moderna Expands Deal With CDMO To Source Raw Material For Coronavirus Vaccine See more from Benzinga * Moderna Expands Deal With CDMO To Source Raw Material For Coronavirus Vaccine * Novavax Analyst Sees Leading Contender In Coronavirus Vaccine Race * Moderna Analyst Says Coronavirus Vaccine Candidate Has 65% Chance Of Success(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Barrons.com

    Moderna’s Covid-19 Vaccine Enters Next Phase of Testing. Goldman Sachs Is Upbeat.

    The biotech company has dosed the first volunteers in the next phase of testing for its vaccine against the Covid-19 virus.

  • Reuters

    U.S. awards new $628 mln contract to boost output of potential COVID-19 vaccine

    The U.S. government on Monday entered into a $628 million contract with drugmaker Emergent BioSolutions to boost manufacturing capacity for a potential COVID-19 vaccine. As drugmakers race to develop vaccines, tests and therapies for COVID-19, the United States is looking to secure manufacturing capacity under its "Operation Warp Speed" program announced in May to accelerate vaccine development. "Securing more manufacturing capacity here in America for candidates that make it to the final stages of Operation Warp Speed will help get a vaccine to American patients without a day wasted," Department of Health and Human Services (HHS) Secretary Alex Azar said in a statement.

  • Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?
    Motley Fool

    Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?

    The coronavirus vaccine race offers these clinical stage companies an opportunity to bring a first product to market -- if all goes well in human trials.

  • Are Moderna’s Coronavirus Gains Over?
    Motley Fool

    Are Moderna’s Coronavirus Gains Over?

    Moderna shares have dropped from a record high. Here’s what hurt the stock -- and what could lead to recovery.

  • Here's the Under-the-Radar Biotech That Could Beat Moderna at Its Own Game
    Motley Fool

    Here's the Under-the-Radar Biotech That Could Beat Moderna at Its Own Game

    Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), who has himself been in the limelight in recent months, even singled out the biotech days ago for what he called its "quite promising" COVID-19 vaccine candidate. Moderna has deservedly received a lot of attention from the press and from investors. This under-the-radar biotech just might even beat Moderna at its own game.

  • Moderna Embarks On Phase 2 Study Of Covid-19 Candidate; Shares Pop 11%
    SmarterAnalyst

    Moderna Embarks On Phase 2 Study Of Covid-19 Candidate; Shares Pop 11%

    Moderna Inc. (MRNA) announced that it has started dosing the first patients in a Phase 2 study with its experimental mRNA-1273 vaccine candidate against the novel coronavirus. Shares shot up 11% to $61.50 on Friday.The Phase 2 study, being conducted by Moderna under its own Investigational New Drug (IND) application, seeks to evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. The biotech company plans to enroll 600 healthy participants across two cohorts of adults ages 18-55 years and older adults ages 55 years and above.Earlier this month, Moderna reported “positive” interim clinical data saying that the Phase 1 study of its mRNA-1273 vaccine candidate produced antibodies that would be able to “neutralize” the virus in patients. The company reiterated plans to start the Phase 3 trial in July, subject to the finalization of the clinical trial protocol.The study will be conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). Funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA), will support the late-stage clinical development programs, as well as the scale-up of mRNA-1273 manufacturing both at the company’s facilities and that of its strategic collaborator, Lonza Ltd.Since the start of the year, the value of Moderna’s shares has more than tripled.Earlier this month, five-star analyst Cory Kasimov at J.P. Morgan reiterated a Buy rating on the stock with a $66.69 price target, saying that there is still much work to be done, risks to navigate, and a lot we don’t actually know.“Moderna may have a viable product on their hands,” Kasimov wrote in a note to investors. “That said, how to appropriately capture this in MRNA's valuation is a tougher question to answer (especially given all the unknowns around COVID-19 and the ultimate opportunity) and one that we suspect will be a key investor debate going forward.”Overall, Wall Street analysts are bullish on Moderna stock awarding 10 Buy and 2 Hold ratings which add up to a Strong Buy consensus. Despite the recent share rally, the $96.75 average price target still indicates a staggering 57% upside potential from current levels. (See Moderna stock analysis on TipRanks).Related News: Efgartigimod’s Positive Data Is Good News for Momenta’s Nipocalimab Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses; Top Analyst Ramps Up PT To $61 Novavax Begins Human Testing For Covid-19 Vaccine, Expects Results In July More recent articles from Smarter Analyst: * Alphabet: Google Discovery Ads Represents Another Opportunity for Investors, Says 5-Star Analyst * Philips Gets FDA Emergency Use Nod For Monitors, Displays During Covid-19 Pandemic * National Instruments To Buy OptimalPlus In $365 Million Deal * 3 "Strong Buy" Penny Stocks That Could Go Boom

  • Bloomberg

    U.S. Cases Rise; Trump G-7 May Draw Fewer Leaders: Virus Update

    (Bloomberg) -- New York is targeting “hotspots” as New York City prepares to reopen in less than two weeks. U.S. cases increased 1.7%, faster than the one-week daily average.Attendance at a June U.S.-hosted meeting of world leaders could shrink because of the outbreak. Siemens Healthineers received U.S. emergency authorization for a coronavirus antibody test.European Union leaders urged the U.S. to reverse a decision to quit the World Health Organization. Italian cases trended lower as the government starts to allow travel, despite objections over letting people leave the hard-hit region near Milan.Key Developments:Virus Tracker: Cases top 6 million; deaths over 367,000Indonesia to open malls, entertainment sites as cases riseTexas shows the world how to reopen cautiously, for nowChinese vaccine expected to begin mass output soonRace to the freezer: Europe’s food glut has nowhere to goPizza chains have windfall on surge in takeout, deliveriesBaseball on ESPN: Korea’s major league plays through outbreakSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click VRUS on the terminal for news and data on the coronavirus. For a look back at this week’s top stories from QuickTake, click here.U.K., France Mull G-7 as Germany Skips (5 p.m. NY)The Covid-19 outbreak may deter German Chancellor Angela Merkel from attending a Group of Seven leaders meeting in the U.S., but other leaders are still in talks with the host, President Donald Trump.Trump spoke with French President Emmanuel Macron on Saturday with “progress on convening the G-7” among the topics, the White House said. On Friday, U.K. Prime Minister Boris Johnson and Trump “discussed the importance of leaders meeting in the U.S. in person, if possible,” according to Johnson’s office. A Merkel spokesman on Saturday said “she’s unable to confirm her personal participation” given the current state of events.The meeting was planned for Trump’s Doral resort in Florida, was moved to Camp David then became a video conference because of the pandemic. Trump is pushing the G-7 leaders to travel to the U.S. for an in-person meeting.U.S. Cases Rise 1.7%, Above Week’s Average (4 p.m. NY)U.S. cases increased 1.7% from the same time Friday, to 1.76 million, according to data collected by Johns Hopkins University and Bloomberg News. The national increase exceeded the average daily increase of 1.3% for the past week and was the biggest percentage rise since May 22. Deaths climbed 1.2% to 103,389.New York reported 1,376 new cases, for a total of 369,660, with 67 deaths -- the same as Friday and the fifth day of fatalities under 75. Deaths totaled 23,848.New Jersey had 910 new cases, pushing the total to 159,608, with 113 new deaths for a total of 11,634, Governor Phil Murphy reported.California reported 2,992 new cases, for a total of 106,878, and added 88 deaths, with the fatality count at 4,156.Pennsylvania reported 680 new cases, for a total of 71,415, and 73 new deaths, to total 5,537, the state health department said.Florida’s cases rose 1.7% to 55,424 and deaths rose to 2,447, the health department said.Greece Allows More Flights from Mid-June (3:30 p.m. NY)Greece will allow visitors from more nations, including the U.S. and U.K., to arrive at Athens and Thessaloniki airports starting June 15, the Foreign Ministry said. After July 1, flights can land at all Greek airports.The government will use the European Union Aviation Safety Agency’s list of airports to determine testing for arriving passengers. If travel originates at an airport not on the affected-area list, then visitors are subject to random tests, the Foreign Ministry said. If the journey begins at an airport on the EASA list, then visitors who test negative will self-quarantine for seven days and if positive will be under supervised quarantine for 14 days.Greece will reopen borders with Albania, Bulgaria and North Macedonia on June 15, the Foreign Ministry said with visitors subject to random tests. Arrivals by sea will begin July 1.French Cases Inch Higher (2:10 p.m. NY)France reported 57 new deaths, raising the total to 28,771, based on hospital data, with reporting of nursing-home fatalities delayed to Tuesday. New cases climbed by 1,828, or 0.8%, to 225,898.FDA Authorizes Siemens Antibody Test (2:10 p.m. NY)Siemens Healthineers AG received U.S. Food and Drug Administration emergency use authorization for a coronavirus antibody test, used to identify recent or prior infection in humans. The company had expected the test to be available by late May and aims to produce more than 50 million tests a month starting in June.N.Y. Targets NYC ‘Hotspots’ (2 p.m. NY)Governor Andrew Cuomo said the state plans to get New York City reopened by focusing on “hotspots” -- neighborhoods where positive cases can be nearly 50% and are largely in minority communities. The city average rate is about 20%.“We have work to do but we’ll still get it done by June 8,” he said.Cuomo also signed a law to compensate the families of hundreds of essential workers who have died in the outbreak.Italy Cases on Declining Trend (12:01 pm NY)Italy reported 416 new cases, up from 516 a day earlier, confirming a declining trend as the total reached 232,664. Total deaths rose to 33,340. The government confirmed plans to allow travel between regions starting June 3 even as some regional governors opposed letting people from the hard-hit Lombardy region move freely.N.Y. Daily Deaths Unchanged (11:45 a.m. NY)New York reported 67 new deaths, Governor Andrew Cuomo said at a Saturday press conference. The figure is the same as reported on Friday and the fifth straight day below 75 fatalities. The state reported 1,376 new cases, for a total of 369,660.U.K. Permits Live Sports Events (11:30 a.m. NY)The U.K. will allow live sports events, without spectators, and further relax restrictions on physical exercise starting Monday as the country eases lockdown measures.Horse racing will be allowed behind closed doors, with other sports like soccer, rugby, cricket, golf and snooker to follow, but without fans, Culture Secretary Oliver Dowden said at a press conference. “British sports recovery has begun,” Dowden said.England’s Premier League plans to resume matches on June 17, after consulting with the clubs, players and managers, Chief Executive Richard Masters said after the government announcement.Spain Deaths Rise (11:25 a.m. NY)The Spanish health ministry said total coronavirus cases increased by 271 to 239,228 in the past 24 hours. Total fatalities rose to 27,125 with 43 new deaths reported in the past seven days.Somalia Votes in 2021, Despite Outbreak (10:30 a.m. NY)Somalia will push ahead with elections in early 2021, Prime Minister Hassan Ali Kheyre said after a cabinet meeting, removing doubt that the spread of Covid-19 will delay the vote.The Horn-of-Africa nation is seeking debt relief as the pandemic adds to its woes, from an insurgency to locusts. It has almost 2,000 cases and a health system ill-equipped to handle the outbreak.South Africa Allows Domestic Flights (10:20 a.m. NY)South Africa will permit air travel from four main airports starting Monday as the nation eases lockdown measures. Limited domestic flights will be allowed for business, and passengers must give a reason, Transport Minister Fikile Mbalula said in a televised briefing on Saturday.India to Ease Lockdown in Stages (8:52 a.m. NY)India announced a phased lifting of the nationwide lockdown by allowing malls, restaurants and places of worship to open from June 8, the interior ministry said in a statement.The country, which had enforced sweeping and strict stay-at-home orders from March 25, will limit the stringent rules to areas that have a large number of active cases. Authorities will decide to open schools and colleges in July, while international air travel will resume in the final phase. The exit plan comes even as India has been unable to flatten its curve despite the restrictions which have left its already troubled economy in deep disrepair.EU Urges U.S. to Reconsider WHO Decision (8:24 a.m. NY)The European Union called on the U.S. to reconsider its decision to terminate its relationship with the World Health Organization, which President Donald Trump has accused of being too deferential to China.“Global cooperation and solidarity through multilateral efforts are the only effective and viable avenues to win this battle the world is facing,” according to a joint statement Saturday from European Commission President Ursula von der Leyen and the bloc’s chief foreign envoy, Josep Borrell. “We urge the U.S. to reconsider its announced decision.”Portugal’s Virus Cases Slow (8:04 a.m. NY)Portugal reported 257 new coronavirus cases on Saturday, taking the total to 32,203, after recording more than 300 infections in each of the two previous days, the government said. The increase in new cases has been mostly in the greater Lisbon area and led the government on Friday to delay the planned reopening of malls in that region. The number of cases in intensive care units fell to 63 on Saturday, remaining at the lowest level since March.Macau’s Economy Shrinks by Almost Half (6:46 a.m. NY)Macau’s economy posted a deeper contraction in the first quarter as lockdown measures introduced to contain the virus outbreak hit revenue from gambling, hotels, and tourism.Gross domestic product in Macau plummeted 48.7% in the first three months of 2020, according to the city’s statistics department. That is the fifth straight quarterly decline.Belgium’s Socialists Propose $41.7 Billion Stimulus (6:14 a.m. NY)Paul Magnette, the head of Belgium’s Socialist party, proposed a 37.6 billion-euro ($41.7 billion) stimulus package to combat the economic toll of the global pandemic, according to an interview with Le Soir. The aid would target catering, cultural and health-care industries, he said.Iran Reports Fewer New Cases (6:12 a.m. NY)Iran’s infection tally rose to 148,950 as the daily number of new cases dropped to 2,282 from 2,819 on Friday, the highest daily number of cases in eight weeks. The virus death toll reached 7,734 with 57 more deaths overnight.S&P Sees Abu Dhabi, Bahrain Economies Shrinking (5:20 p.m. HK)Abu Dhabi’s economy will contract 7.5% this year, S&P Global Ratings said, citing lower oil production and the pandemic.Bahrain’s economy will shrink 5% this year because of low oil prices, although government stimulus measures should provide some support, S&P said. The ratings company expects Bahrain’s economy to rebound in 2021 as oil prices recover and regional activity increases.Indonesia Gears Up for Post-Holiday Return (5:02 p.m. HK)Indonesia’s capital Jakarta is anticipating one million vehicles will enter the city as people return from Eid al-Fitr holidays. Traffic, including motorcycles, is projected to peak from Saturday to Monday, according to a Cabinet Secretariat statement. While the figure is lower compared to the 2.8 million vehicles recorded last year, the flow of so many travelers is raising concern as the nation’s coronavirus cases grow.Indonesia now has the highest coronavirus death toll in Southeast Asia, with 1,573 people succumbing to the disease as of Saturday. New cases have more than doubled in May, with the total reaching 25,773.Uzbekistan Extends Lockdown (3:36 p.m. HK)The Uzbek government has decided to extend lockdown restrictions until June 15. Central Asia’s most populous nation has confirmed 3,513 cases of infection of the coronavirus, with 14 deaths and 2,728 recoveries.Singapore Reports 506 New Cases (3:30 p.m. HK)Singapore reported 506 new infections as of Saturday, according to a statement from its Health Ministry. A vast majority of the additional infections are of work permit-holders who live in foreign workers’ dormitories, according to the statement. The ministry is expected to provide additional details in the evening, it added.Chinese Vaccine Expected to Begin Mass Output This Year (3:25 p.m. HK)A front-running Covid-19 vaccine being developed in China is expected to be available as soon as the end of this year, according to a report published in the official Wechat account of the State-owned Assets Supervision and Administration Commission.The vaccine, jointly developed by the Beijing Institute of Biological Products and China National Biotec Group Co., has completed phase II testing and may be ready for the market at the end of this year or early next year, said the report.The production line for the vaccine will be fully disinfected and closed in preparation for output to start Saturday, and will have a manufacturing capacity of 100 million-120 million vaccines each year.Iran Lifts Restriction on Shopping Hours (2:26 p.m. HK)Iran has lifted a restriction on the operating hours of shopping malls in the latest step of reopening the economy. Meanwhile, all mosques in the country will be open to worshipers for daily prayers three times a day, President Hassan Rouhani said in a national coronavirus taskforce briefing broadcast on state TV.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Investors Are Jumping the Gun on Moderna's Vaccine Results
    Motley Fool

    Investors Are Jumping the Gun on Moderna's Vaccine Results

    Shares of Moderna (NASDAQ: MRNA) were soaring earlier this month when the company released interim results from its mRNA vaccine. Investors were bullish on the possible COVID-19 vaccine, sending the stock to an all-time high of $87. Coronavirus stocks like Moderna are especially volatile surrounding news related to any treatments or vaccines.

  • Why Moderna Stock Jumped 10.7% Today
    Motley Fool

    Why Moderna Stock Jumped 10.7% Today

    Shares of Moderna (NASDAQ: MRNA) rose more than 10% on Friday after the biotechnology company announced the commencement of its Phase 2 study for its novel coronavirus vaccine. Moderna said the first participants in each age group of its Phase 2 study have received doses of its experimental COVID-19 vaccine, mRNA-1273. Moderna is seeking to enroll 600 healthy participants, including 300 people aged 18-55 and 300 people older than 55.